Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|June 21, 2012
Industry Briefs: June 18, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Advertisement
Company News
Amgen has completed its acquisition of the Turkish company, Mustafa Nevzat Pharmaceuticals.
Dalton Pharma Services and Clarity Pharmaceuticals have entered into a manufacturing-services agreement under which Dalton Pharma Services will provide cGMP chemistry manufacturing, scale-up, aseptic fill–finish services, and analytical support for Clarity’s positron emission tomography-based companion diagnostics and radio-immunotherapeutics development program.
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM has signed a commercial agreement for contract manufacturing services using its proprietary XD high cell-density process technology with an undisclosed pharmaceutical company.
In other news, Royal DSM’s tender offer to purchase all outstanding shares of common stock of the medical-device company Kensey Nash at a price of $38.50 per share was successful.
Frazier Healthcare has acquired Catalent Pharma Solutions's US commercial pharmaceutical-packaging operations, based in Philadelphia, Pennsylvania, and Woodstock, Illinois.
JDRF and Novo Nordisk have established an R&D collaboration for disease-modifying immunotherapies for Type I diabetes.
Merck & Co. and Ambrx have agreed to design and develop rationally optimized biologic drug conjugates based on Ambrx’s site-specific protein medicinal chemistry technology.
Roche’s Genentech has entered into a CHF 400-million ($418 million) agreement with AC Immune for developing anti-Tau antibodies for treating Alzheimer’s disease.
Unilife has entered into a seven-year commercial supply contract with an undisclosed pharmaceutical company for the use of its Unifill prefilled syringe.
Waters has began construction on its new mass spectrometry headquarters in Wilmslow, United Kingdom.
People News
AMRI has appointed Srinivas Nanduri as director of medicinal chemistry at the company’s research center in Hyderabad, India, reporting to Subramanyam Maddala, president of AMRI’s India operations. In addition, Suneel Kumar Bommisetty was named senior research associate of computational chemistry, reporting to Nanduri.
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement